Patient Journey and the Role of the Pharmacist
February 17th 2025Panelists discuss how the TD patient journey often begins with subtle symptoms that may go unrecognized, particularly in older adults who face unique challenges with diagnosis and treatment, while emphasizing the crucial role pharmacists play in early identification through medication reviews, regular monitoring of patients on antipsychotics, coordination with healthcare providers, and ongoing assessment of treatment response and adherence.
Strategies for Optimizing Therapy
February 17th 2025Panelists discuss how barriers to optimizing TD therapy include insurance coverage limitations, high medication costs, delayed diagnosis, lack of provider awareness, and stigma associated with movement disorders, while highlighting strategies like patient assistance programs, early screening protocols, provider education initiatives, and collaborative care models to overcome these obstacles and improve access to effective treatment.
Partnering for Women’s Health: The Pharmacist’s Collaborative Role
February 13th 2025Panelists discuss how health care professionals collaborate through interdisciplinary teams, integrated care coordination, and lifecycle-specific approaches to provide comprehensive women’s health care, addressing gaps by implementing patient-centered, culturally sensitive models that prioritize holistic well-being across different life stages.
Strategies for Addressing Unmet Needs in Women’s Health and Supporting Women During Menopause
February 13th 2025Panelists discuss how menopause marks a significant life transition, characterized by hormonal decline, reproduction cessation, and unique physiological changes requiring medical and emotional support. Health care professionals guide women through life’s reproductive stages, providing comprehensive health care from menarche to post menopause, focusing on individualized prevention of symptom management, and holistic well-being across hormonal transitions.
From Menarche to Postmenopause: The Vital Role of Pharmacists in Women’s Health
February 13th 2025Panelists discuss how menopause marks a significant life transition, characterized by hormonal decline, reproduction cessation, and unique physiological changes requiring medical and emotional support. Health care professionals guide women through life’s reproductive stages, providing comprehensive health care from menarche to post menopause, focusing on individualized prevention of symptom management, and holistic well-being across hormonal transitions.
Shared Decision-Making in Tardive Dyskinesia
February 10th 2025Panelists discuss how TD treatment can be optimized through individualized approaches that consider patient-specific factors like symptom severity, comorbidities, concurrent medications, and daily routines, utilizing tools like titration kits to carefully adjust VMAT2 inhibitor dosing while monitoring response and tolerability to achieve the best possible outcomes for each patient.
Management of Tardive Dyskinesia and Comorbidities
February 10th 2025Panelists discuss how managing tardive dyskinesia in patients with comorbid mental health conditions requires a delicate balance between treating TD symptoms while maintaining psychiatric stability, emphasizing the importance of coordinated care between psychiatrists and movement disorder specialists to optimize medication regimens, monitor for potential drug interactions, and address the complex interplay between physical symptoms and psychological well-being.
Pharmacists Play Pivotal Roles in Outpatient CAR T-Cell Therapy
February 9th 2025Molly Schiffer, PharmD, BCOP, discusses the logistical and operational challenges of delivering outpatient CAR T-cell therapy, emphasizing the benefits of outpatient treatment, including reduced costs, improved access to therapy, and better quality of life for patients.
Pharmacists Play a Vital Role in Addressing Patient Leakage in the Precision Medicine Care Continuum
February 6th 2025Edward Kim, MD, MBA, discusses critical points of patient leakage in precision medicine, emphasizing the role of multidisciplinary teams in streamlining care, managing medications, and improving patient outcomes.
Bridging Gaps in Precision Medicine: Overcoming Patient Leakage and Advancing Personalized Care
February 5th 2025Edward Kim, MD, MBA, highlights the challenges of patient disengagement, data fragmentation, and provider education in precision medicine, emphasizing the need for personalized approaches to enhance patient outcomes, particularly in oncology.
Additional Considerations With PBC Therapies
February 5th 2025Panelists discuss how recent FDA regulatory actions regarding obeticholic acid have raised concerns about its long-term safety profile and accessibility, leading health care teams to develop strategies for supporting patients through treatment transitions while navigating insurance coverage and access challenges for newer primary biliary cholangitis (PBC) therapies.
Advancing Cancer Care: The Role of Radiopharmaceuticals in Precision Medicine
February 3rd 2025Naga Vara Kishore Pillarsetty, PhD, discusses advancements in radiopharmaceuticals for cancer therapy, noting common supply chain challenges, radiation safety measures, and patient misconceptions with the use of these drugs.
Safety Profile of VMAT2 Inhibitors and Impact on Treatment Selection
February 3rd 2025Panelists discuss how VMAT2 inhibitors' most commonly reported adverse effects include somnolence, fatigue, and mild parkinsonism symptoms, which can typically be managed through dose adjustments and careful titration strategies, while noting these side effects are generally less severe than those of older treatments and rarely lead to discontinuation when patients are properly monitored and educated about expectations.
Long-Term Outcomes with VMAT2 Inhibitors
February 3rd 2025Panelists discuss how long-term open-label extension studies of VMAT2 inhibitors demonstrated sustained efficacy and tolerability of both deutetrabenazine (ARM-TD and AIM-TD extensions showing durable response over 3 years) and valbenazine (KINECT 4 showing maintained improvements through 48 weeks), with low discontinuation rates due to adverse events and no new safety signals emerging during extended treatment periods.
Monitoring Patients Transitioning From Obeticholic Acid
January 29th 2025Panelists discuss how transitioning patients from obeticholic acid to seladelpar or elafibranor requires close monitoring of liver biochemistry, pruritus severity, medication adverse effects, and quality of life measures while providing clear patient education about expected timeline for symptom improvement and potential adjustment periods.